secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001516551-25-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025
--------------------------------------------------------------------------------

- Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
- Cash, equivalents & short-term investments $48.6M as of June 30, 2025; expected to fund operations through at least Q1 2027.
- Phase 2a CBeyond study of nimacimab top-line data expected late Q3/early Q4 2025; extension study enrolling.
- Preclinical data: nimacimab + low-dose tirzepatide boosted weight loss beyond optimal tirzepatide; nimacimab reduced post-treatment weight rebound.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/0001516551-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001516551-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer